logo
  

American Electric Power Q3 Profit Matches Estimates - Quick Facts

American Electric Power (AEP) reported third-quarter net earnings of $493 million or $1.01 per share, compared to $433 million or $0.89 per share, last year. Operating earnings was $493 million or $1.01 per share, for the quarter.

On average, 15 analysts polled by Thomson Reuters expected the company to report profit per share of $1.01 for the quarter. Analysts' estimates typically exclude special items.

Revenue increased to $4.3 billion from $4.2 billion, a year ago. Analysts expected revenue of $4.43 billion for the quarter.

Management narrowed its 2014 operating earnings guidance range to $3.40 to $3.50 per share from $3.35 to $3.55 per share. Analysts expect the company to report 2014 earnings per share of $3.47.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. (UBER) reported Wednesday a net loss for the first quarter that sharply widened from last year, hurt by a huge net unrealized loss related to the revaluation of Uber's equity investments. Loss per share for the quarter missed analysts' expectations, while quarterly revenues topped it. Shares of Siemens Energy AG were gaining more than 12 percent in German trading after the company on Wednesday raised its outlook for fiscal 2024 after reporting a profit in its second quarter, compared to last year's loss, amid positive market environment. Meanwhile, second-quarter orders were lower than last year, and the company maintained annual earnings forecast. AstraZeneca, a major provider of Covid-19 vaccines across the world mainly during the initial pandemic period, has initiated a process to withdraw its Vaxzevria COVID-19 vaccine worldwide, citing weak demand and the surplus availability of new vaccines. Meanwhile, AstraZeneca reportedly had admitted recently in court documents that the vaccine could cause side-effects such as blood clots...

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
Follow RTT